Background
==========

In 2009, tuberculosis (TB) was the world's 7th leading cause of death, resulting in 1.7 million deaths worldwide, more than 9.4 million new infections and 14 million prevalent cases \[[@B1]\]. TB is often known as "a disease of the poor" because the burden of TB follows a strong socioeconomic gradient both between and within countries, and also within the poorest communities of countries with high TB incidence \[[@B2]\]. Some studies have shown a strong association between poverty and TB and have demonstrated that poor and vulnerable groups are at an increased risk of TB infection, have a higher prevalence of disease, have worse outcomes (including mortality), and display worse TB care-seeking behaviors \[[@B3]-[@B8]\]. Risk factors for these TB-related outcomes include structures, behaviors and other diseases commonly associated with poverty - overcrowded living or working conditions, poor nutrition, smoking, alcoholism, diabetes, exposure to indoor air pollution and HIV \[[@B2],[@B7]-[@B10]\].

It is also well-known that TB can contribute to poverty by reducing patients' physical strength and ability to work \[[@B8],[@B11]-[@B13]\]. However, another pathway through which TB can affect households' economic situation, the costs patients incur when utilizing TB care, has been less studied. These costs include both direct out-of-pocket costs incurred when seeking treatment and care and the indirect, or time costs, associated with utilizing healthcare. While most countries with high TB burden provide free sputum smear microscopy for patients with suspected pulmonary TB, more than half of these 22 countries charge for other TB-related diagnostic tests such as radiography, sputum culture, and drug-susceptibility testing \[[@B14]\]. Under Directly Observed Therapy Short-course (DOTS) programs, all high burden TB countries provide free first line anti-TB medication, but many patients purchase anti-TB drugs in private pharmacies (some without prescriptions), which can be costly \[[@B14],[@B15]\]. In high TB burden countries, 60% of overall health expenditure is in the private sector, and a large proportion of these expenditures are paid out-of-pocket by patients \[[@B14]\].

A number of previous studies have documented the downstream consequences of the direct and indirect costs that TB patients incur. More than 50% of TB patients have been reported to experience financial difficulties due to TB \[[@B16]\], and these costs can be "catastrophic" in that they amount to more than 10% of patients' or households' annual income \[[@B17]-[@B19]\]. TB patient costs have been shown to lead to reduced food consumption, diversion of resources from other types of healthcare, taking children out of school, and borrowing or selling assets \[[@B17],[@B19]-[@B21]\]. Furthermore, financial constraints have been shown to predict non-adherence to TB medication \[[@B16]\]. In general, the World Health Organization (WHO) estimates that 100 million people every year fall into poverty from paying for health services \[[@B22]\].

One earlier review reports on the overall costs TB-patients in Africa face during the pre- and post-diagnosis phases of TB treatment and care as well as coping mechanisms for catastrophic costs \[[@B23]\]. In this study, we expand on this previous assessment by broadening the evidence base on TB patient costs in sub-Saharan Africa through screening of additional databases and broadening the study design inclusion criteria, systematically identifying the particular types of TB patient costs (both direct and indirect), systematically reviewing the evidence on the cost quantities for each cost type, and providing benchmarks for the magnitude of cost burdens on TB patients and households.

Methods
=======

Data sources and search strategies
----------------------------------

We used eight electronic databases to identify papers reporting on patient costs for TB care in sub-Saharan Africa available by January 3-4, 2011: PubMed, Embase, Science Citation Index, Social Science Citation Index, EconLit, Dissertation Abstracts, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Sociological Abstracts. Each search strategy comprised a Boolean operator of "and" with two elements: tuberculosis and cost/economic aspects. For the PubMed search, MeSH and "all fields" terms comprising tuberculosis and OR fields for cost estimates such as "employment," "out of pocket," "patient costs" and MeSH terms for "costs and cost analysis" were used. Similar search strategies were employed for the other 7 databases (see Additional file [1](#S1){ref-type="supplementary-material"} for the precise search algorithms for each database). Each database was searched from the earliest referenced publication date through January 1, 2011. Studies were included regardless of language. Two reviewers independently screened articles identified from the initial search of the databases by title and/or abstract.

To identify additional articles, conference abstracts written in English from 1994-2010 from the International Union Against Tuberculosis and Lung Disease (IUATLD) annual conference were searched. Furthermore, we performed a secondary search of reference lists of articles identified through the database search, including both the primary studies included in our synthesis and review studies.

Articles were considered for inclusion if they contained a quantitative measure of a direct or indirect patient-incurred cost (including time costs) relating to TB treatment or care for adult pulmonary tuberculosis. Following Rajeswari et al. \[[@B24]\] and Jackson et al. \[[@B25]\] we defined costs as follows: Direct costs included both medical expenditures (such as consultation fees or costs of medication or diagnostic tests) and non-medical expenditures (such as money spent on travel, lodging, and food for both patients and caregivers). Indirect costs were defined as time costs associated with utilizing healthcare, or time costs converted into monetary units based on loss of wages for both patients and caregivers or decreased earning ability \[[@B26]\].

We excluded the following articles: i) published before 1994 when DOTS was officially launched as a framework for a TB control strategy recommended by the WHO \[[@B27]\]; ii) not taking place in Sub-Saharan Africa; iii) not pertaining to TB; iv) not involving human subjects; v) on MDR-TB, HIV/TB co-infection, latent or pediatric TB; vi) focusing solely on diagnostic tests, screening tests, or vaccinations; vii ) not containing any primary data on cost estimates or economic analysis; or viii) not relating to individual patient costs.

Articles were assessed for study quality. In particular, we examined the studies to ensure that we included only those in our final review that had clearly defined objectives, clearly defined study populations, and a quantitative measure of patient-costs. Additionally, articles were categorized by study type and whether costs were incurred pre- or post-diagnosis. We adhered to the PRISMA guidelines \[[@B28]\].

Data extraction and analysis
----------------------------

In addition to study-specific variables (authors, study type, year, location, setting, period of observation, population under study, and study objectives), the two reviewers extracted patient-borne quantitative direct and indirect cost measurements. We extracted only costs measured empirically in the reviewed studies. Costs that were extrapolated or projected in mathematical models were not included in the analysis. Data were categorized into costs related to health insurance, prepayment, consultation or provider fees, hospitalization, medication, and diagnostic test costs, traditional healer and food costs, travel costs, time costs, reported impact on income, reported direct, indirect, and total costs, caregiver costs and catastrophic costs.

To compare costs expressed in different currencies and measured in different years, we converted all cost 180 estimates into 2010 international dollars (I\$). We rounded all cost estimates to the nearest integer except for costs less than 1I\$, which we rounded to the second decimal place. For costs that were presented in US\$, costs were first converted to respective local currency units using OANDA currency conversions \[[@B29]\] based on exchange rates at the commencement of the study period. For studies that did not specify the year or period of currency estimates, January 1^st^ of the beginning of the study year was used as a standard conversion date except for one study in Botswana \[[@B30]\], for which conversion rates were only available beginning November 1, 1993 instead of January 1, 1993, and for one study in Uganda \[[@B31]\], for which conversion rates were available beginning January 1, 1996 instead of January 1, 1992. Next, local currency units were adjusted to 2010 rates using the International Monetary Fund's database on average consumer price inflation over time \[[@B32]\]. Finally, costs were adjusted to 2010 international dollars based on the World Bank's purchasing power parity (PPP) conversion factors (in local currency units per international dollar) \[[@B33]\].

To compare costs across studies, we report travel costs as single visit costs and hospitalization costs over the entire treatment period. To provide a benchmark for the magnitude of cost burdens of TB care on patients, we expressed the expenditures as percentage of per-capita annual (or monthly) GDP (in I\$) of the country and in the year when the study, which generated the cost estimates, was conducted. The per-capita GDP figures are taken from the *World Development Indicators* published by the World Bank \[[@B33]\]. Per-capita GDP, i.e., the average income, is one benchmark that is meaningful to understand and commonly used for such purposes, and we thus use it here. However, since TB is a disease that predominantly affects poorer populations, we also express the cost estimates as a percentage of an alternative income benchmark---the per-capita income of the income-poorest 20% of the population, calculated according to the following equation:

$$\frac{\text{Total GDP}*\text{Income share of the income}\text{-}\text{poorest}\ 20\%\ \text{of the population}}{\text{Total population size}*0.2}$$

We chose these two income benchmarks, rather than study population-specific incomes, because very few of the studies included in our review reported the study population income. We also report whether the patient costs of TB treatment are "catastrophic" for the person of average income or the person of average income amongst the income-poorest 20% of the population, classifying costs as "catastrophic" when they were at least 10% of average annual income for the respective population. While definitions of catastrophic expenditures commonly relate to household income, \[[@B18],[@B34]-[@B37]\] we chose to use 10% of annual individual income as a benchmark for catastrophic costs because for most studies we lack household-level income data as well as the household-level TB data that would be necessary to judge whether the financial burdens of TB care and treatment is "catastrophic" or not. Without the latter data, household-level income data is not an appropriate indicator since TB tends to cluster in households \[[@B38]-[@B40]\].

Results
=======

5,114 articles were identified from the initial search of the eight databases. After excluding 1,112 duplicate articles, 1,510 were excluded because they did not include TB as a major subject heading, 777 did not include cost estimates, 632 were published before 1994, 427 focused solely on diagnostic tests, screening tests or vaccinations, 331 did not include patient cost estimates, and 95 did not involve human subjects. Reviewing the full text of the remaining 230 articles, we found that 55 did not include a quantitative cost measurement; 14 were reviews, commentaries, letters or editorials that did not include primary data; 7 were on pediatric TB, 13 on MDR-TB, 6 on latent TB, 4 on HIV/TB, 105 studies did not take place in sub-Saharan Africa; and 2 studies were by the same authors and included the same data (leading to the exclusion of 1 of the 2 studies). This selection process resulted in 25 relevant studies; 5 additional relevant publications were identified through the search of the conference database and reference lists, so that a total of 30 articles were included in the final synthesis of our review (see Figure [1](#F1){ref-type="fig"}).

![Flowchart of the systematic review.](1471-2458-12-980-1){#F1}

Table [1](#T1){ref-type="table"} describes each of the 30 studies in terms of their study populations, main objectives, types of cost estimates, and time period in which costs were incurred (pre- vs. post-diagnosis). Eight studies reported direct costs, one study reported indirect costs, and twenty-one studies reported both indirect and direct costs. Table [2](#T2){ref-type="table"} describes the cost categories, including definitions for each cost type, whether the costs are considered direct or indirect, whether the cost are incurred pre- or post-diagnosis, the number of studies reporting a particular cost type, and the cost range and median among all studies reporting the cost type.

###### 

Summary of Studies

  **Author (Year)**                               **Country**    **Type of study**             **Population under study**                                                                                                                                                                                                                                         **Primary objectives**                                                                                                                                                                                                                        **Types of costs reported**                                                                                                            **Time period of costs (Pre vs. post diagnosis)**
  ----------------------------------------------- -------------- ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  Aspler, et al. (1998) \[[@B41]\]                Zambia         Cross-sectional               103 patients aged ⩾18 years with active or extra-pulmonary TB who had been on treatment for 6-10 weeks                                                                                                                                                             To estimate TB patient costs for treatment and diagnosis and cost determinants                                                                                                                                                                Pre-diagnosis, treatment, time, travel, medication, consultation, hospitalization, food, health insurance, and diagnostic test costs   Both
  Awofeso, N. (1998) \[[@B42]\]                   Nigeria        Prospective cohort            2144 symptomatic smear-positive patients in two study periods                                                                                                                                                                                                      To discuss the implications of pre-payment versus free medication therapy on treatment and case-finding of TB patients                                                                                                                        Medication costs                                                                                                                       Post-diagnosis
  Bevan, E. (1997) \[[@B43]\]                     Kenya          Unknown                       Unknown                                                                                                                                                                                                                                                            Letter to describe other costs associated with DOTS                                                                                                                                                                                           Daily inpatient care, travel, and other medical expenses                                                                               Post-diagnosis
  Brouwer, et al. (1998) \[[@B44]\]               Malawi         Cross-sectional               89 smear-positive pulmonary TB patients admitted to Queen Elizabeth Central Hospital                                                                                                                                                                               To investigate how TB patients utilize traditional healers and traditional medicine in their care-seeking behaviors                                                                                                                           Total fixed and variable costs, time, and traditional healer costs                                                                     Pre-diagnosis
  Cambanis, et al. (2005) \[[@B45]\]              Ethiopia       Cross-sectional               243 patients undergoing sputum examination for TB diagnosis                                                                                                                                                                                                        To assess factors related to patient delay in presenting to health services for the diagnosis of TB                                                                                                                                           Time and travel costs                                                                                                                  Pre-diagnosis
  Chard, S. (2001) \[[@B46]\]                     Uganda         Cross-sectional               89 female patients aged ⩾18 years identified from a TB clinic                                                                                                                                                                                                      To examine treatment seeking, health beliefs, and social networks of female Ugandan TB patients                                                                                                                                               Time, travel, medication, traditional healers, and costs for "tipping" healthcare providers                                            Both
  Chard, S. (2009) \[[@B47]\]                     Uganda         Cross-sectional               65 women aged ⩾18 years with a diagnosis of pulmonary TB, and receiving outpatient TB treatment from one of three TB clinics                                                                                                                                       To explore the TB treatment-seeking process of Ugandan women in order to determine the routes to effective government TB treatment                                                                                                            Private providers and traditional healer costs                                                                                         Both
  Datiko and Lindtjørn (2010) \[[@B48]\]          Ethiopia       Cost-effectiveness analysis   229 smear-positive patients                                                                                                                                                                                                                                        To determine the cost and cost-effectiveness of involving health extension workers in TB treatment under a community-based model                                                                                                              Time, caregiver, food, direct, and total costs                                                                                         Post-diagnosis
  Edginton, et al. (2002) \[[@B49]\]              South Africa   Qualitative                   114 hospital TB patients and 75 clinic TB patients and community members were interviewed                                                                                                                                                                          To assess the beliefs and experiences about TB from the perspective of patients and community members in order to assess the impact of presentation to health services and treatment adherence                                                Time and travel costs                                                                                                                  Post-diagnosis
  Floyd, et al. (2003) \[[@B50]\]                 Malawi         Cost-effectiveness analysis   2,174 new smear-positive and -negative patients registered for treatment in 1997; 2,821 new smear-positive and -negative patients registered for treatment in 1998                                                                                                 To assess the cost and cost-effectiveness of new treatment strategies for new pulmonary TB patients introduced in Malawi in 1997                                                                                                              Time, travel, hospitalization, caregiver, and DOTS costs                                                                               Post-diagnosis
  Floyd, et al. (1997) \[[@B51]\]                 South Africa   Cost-effectiveness analysis   New smear-positive adult patients                                                                                                                                                                                                                                  To conduct an economic evaluation of directly observed treatment and conventionally delivered treatment for the management of new adult TB cases                                                                                              Time, travel, hospitalization, total, and DOTS costs                                                                                   Post-diagnosis
  Gibson, et al. (1998) \[[@B52]\]                Sierra Leone   Cross-sectional               54 inpatients, 18 outpatients, and 17 staff members in 6 TB Centers                                                                                                                                                                                                To evaluate the impact of patient poverty and staff salaries on patient costs for TB treatment within a sub-national TB program                                                                                                               Pre-program, program time, and total costs                                                                                             Both
  Harper, et al. (2003) \[[@B53]\]                The Gambia     Qualitative                   443 patients and clinic staff participated in focus groups, in-depth interviews, and semi-structured interviews                                                                                                                                                    To evaluate the factors related to shortages of case tracing and adherence to treatment using qualitative methods with a cohort of TB patients                                                                                                Travel and private treatment costs                                                                                                     Both
  Kemp, et al. (2007) \[[@B54]\]                  Malawi         Cross-sectional               179 smear-positive and -negative TB patients who were in the intensive phase of treatment                                                                                                                                                                          To assess the relative costs of accessing a TB diagnosis for the poor and for women in urban Lilongwe, Malawi, where public health services are accessible within 6km and are provided free of charge                                         Time, travel, medication, and food costs                                                                                               Both
  Mesfin, et al. (2010) \[[@B55]\]                Ethiopia       Prospective cohort            537 newly diagnosed smear-positive pulmonary TB patients and 387 newly diagnosed smear-negative pulmonary TB patients ≥15                                                                                                                                          To investigate costs of TB diagnosis incurred by patients, their escorts, and the public health system in 10 districts in Ethiopia                                                                                                            Caregiver, time, travel, medication, consultation, hospital admission, and lodging costs                                               Both
  Moalosi, et al. (2003) \[[@B56]\]               Botswana       Cost-effectiveness analysis   50 caregivers of TB patients on home-based care                                                                                                                                                                                                                    To determine the affordability and cost-effectiveness of home-based DOTS vs. hospital-based DOTS for TB patients and to describe the characteristics of patients and their caregivers                                                         Total, time, travel, medication and hospitalization costs for caregivers                                                               Both
  Needham, et al. (1996) \[[@B57]\]               Zambia         Cross-sectional               23 adult inpatients and outpatients with a diagnosis of pulmonary TB                                                                                                                                                                                               Letter in response to Pocock et al. 1996 to assess patient-related economic barriers to TB diagnosis in Lusaka, Zambia                                                                                                                        Medical, non-medical, time, and caregiver costs                                                                                        Both
  Needham, et al. (1998) \[[@B58]\]               Zambia         Cross-sectional               202 adult inpatients and outpatients registering with new pulmonary TB at the Chest Clinic                                                                                                                                                                         To study the pre-diagnosis economic impact burden and barrers to care seeking for TB patients in urban Zambia                                                                                                                                 Time, travel, consultation, caregiver, private provider, traditional healer, insurance, diagnostic, treatment, and food costs          Both
  Needham, et al. (2004) \[[@B59]\]               Zambia         Qualitative                   202 adult patients with pulmonary tuberculosis                                                                                                                                                                                                                     To assess the barriers to successful care seeking faced by TB patients in urban Zambia                                                                                                                                                        Time, travel, caregiver, and government health insurance costs                                                                         Pre-diagnosis
  Nganda, et al. (2003) \[[@B60]\]                Kenya          Cost-effectiveness analysis   New smear-positive, new smear-negative and extra-pulmonary adult patients; for each type of patient, two alternative approaches to treatment were evaluated: the conventional approach used until September 1997 and the new approach introduced in October 1997   To assess the cost and cost-effectiveness of new treatment strategies, involving decentralization of care from hospitals to peripheral health facilities and the community, compared to the conventional approaches used until October 1997   Total, travel, hospitalization, TB clinic, and DOTS costs                                                                              Post-diagnosis
  Okello, et al. (2003) \[[@B61]\]                Uganda         Cost-effectiveness analysis   New smear-positive pulmonary patients under two strategies: the conventional hospital-based approach used from 1995 thorough 1997, and the new community-based approach introduced in 1998                                                                         To assess the cost and cost-effectiveness of conventional hospital-based care with the new community-based care for new smear-positive pulmonary TB patients                                                                                  Time, travel, hospitalization, and total DOTS costs                                                                                    Post-diagnosis
  Pocock, et al. (1996) \[[@B62]\]                Malawi         Cross-sectional               100 adult patients with smear-positive and extrapulmonary TB admitted to the TB ward, Queen Elizabeth Central Hospital, for 2 months of treatment                                                                                                                  Letter investigating impacts of long hospitalization from the patients' perspective                                                                                                                                                           Time costs                                                                                                                             Post-diagnosis
  Saunderson, P.R. (1995) \[[@B31]\]              Uganda         Cost-effectiveness analysis   34 patients attending a hospital run by a non-governmental organization                                                                                                                                                                                            To analyze the costs and cost-effectiveness of the current TB control strategy and an alternative ambulatory treatment strategy                                                                                                               Total, time, hospitalization, and pre-diagnosis costs                                                                                  Both
  Sinanovic, et al. (2003) \[[@B63]\]             South Africa   Cost-effectiveness analysis   New smear-positive and retreatment pulmonary TB patients started on treatment in two townships of Metropolitan Cape Town (Guguletu, where both clinic and community care were provided, and Nyanga, whereonly clinic-based care was provided)                      To evaluate the affordability and cost-effectiveness of community involvement in TB care                                                                                                                                                      Total, time, and travel costs                                                                                                          Post-diagnosis
  Sinanovic and Kumaranay-ake (2006) \[[@B64]\]   South Africa   Cost-effectiveness analysis   1,182 new sputum positive patients at 2 public-private workplace sites (PWP), 2 public-non-governmental organization partnership sites (PNP) and 2 purely public sites                                                                                             To estimate the cost and cost-effectiveness of different types of public-private-partnerships in TB treatment and the financing required for the different models from the provincial TB program from the patient and provider perspective    Total, time, and travel costs                                                                                                          Post-diagnosis
  Steen and Mazonde (1999) \[[@B30]\]             Botswana       Cross-sectional               212 New and retreated patients with smear-positive pulmonary TB                                                                                                                                                                                                    To estimate the health-seeking behaviors of TB patients and their beliefs and attitudes of the disease                                                                                                                                        Outpatient fees                                                                                                                        Post-diagnosis
  Vassall, et al. (2010) \[[@B65]\]               Ethiopia       Cross-sectional               250 patients ⩾ 15 years using TB-HIV pilot services and diagnosed with and being treated for TB, HIV, or both                                                                                                                                                      To measure patients costs of TB-HIV services from hospital-based pilot sites for collaborative TB-HIV interventions                                                                                                                           Direct, indirect, transport, total                                                                                                     Both
  Wandwalo, et al. (2005) \[[@B66]\]              Tanzania       Cost-effectiveness analysis   42 treatment supervisors and 103 new smear-positive, smear-negative, and extrapulmonary TB patients 5 years                                                                                                                                                        To determine the cost and cost-effectiveness of community-based DOTS versus health facility treatment of TB in urban Tanzania                                                                                                                 Direct, indirect, time, and total costs                                                                                                Post-diagnosis
  Wilkinson, et al. (1997) \[[@B67]\]             South Africa   Cost-effectiveness analysis   TB patients under the Hlabisa strategy (1991-preent), the former Hlabisa strategy (until 1991), the Department of Health strategy, and the SANTA strategy based on sanatorium care                                                                                 To conduct an economic analysis of the Hlabisa community-based DOTS management compared to three alternative strategies                                                                                                                       Total, hospitalization, and travel costs                                                                                               Post-diagnosis
  Wyss, et al. (2001) \[[@B68]\]                  Tanzania       Cross-sectional               191 TB cases in 3 surveillance areas who had smear-positive, extrapulmonary, or relapse TB                                                                                                                                                                         To assess household level costs of TB and to compare them with provider costs of the National TB Control Program                                                                                                                              Diagnostic test, time, traditional healer, private provider, hospitalization, caregiver, and travel costs                              Both

###### 

Types of Costs

  **Cost categories**               **Definition**                                                                                                                                                                                                                                                                                                                                                                     **Direct or indirect**   **Pre- or post-diagnosis**   **Number of studies reporting cost category**   **Range (median) of costs**
  --------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------ ---------------------------- ----------------------------------------------- ------------------------------
  Health insurance                  Costs required for national health insurance schemes to finance TB care                                                                                                                                                                                                                                                                                                            Direct                   Pre-diagnosis                2                                               I\$2- I\$3 (I\$2)
  Consultation or prepayment fees   Costs charged by providers before diagnosis or treatment                                                                                                                                                                                                                                                                                                                           Direct                   Pre-diagnosis                4                                               I\$2- I\$7 (I\$3)
  Private provider fees             Costs charged in the private sector rather than the public sector                                                                                                                                                                                                                                                                                                                  Direct                   Both                         4                                               I\$24- I\$141 (I\$41)
  Hospitalization                   Costs associated with hospitalization due to TB                                                                                                                                                                                                                                                                                                                                    Direct                   Post-diagnosis               10                                              I\$1- I\$530 (I\$80)
  Medication                        Costs of medications including standard TB treatment under non-DOTS systems and other drugs                                                                                                                                                                                                                                                                                        Direct                   Post-diagnosis               5                                               I\$15- I\$548 (I\$21)^a^
  Diagnostic tests                  Costs for tests other than sputum microscopy such as x-rays, chest radiographs, or other laboratory tests                                                                                                                                                                                                                                                                          Direct                   Pre-diagnosis                3                                               I\$7- I\$10 (I\$9)
  Traditional healer                Costs associated with seeking traditional healers before Western medical care                                                                                                                                                                                                                                                                                                      Direct                   Pre-diagnosis                5                                               I\$4- I\$563 (I\$15)
  Food                              Costs for regular food and food separate from normal diets such as potatoes, eggs, meat, fruit, and soft drinks \[[@B58]\]                                                                                                                                                                                                                                                         Direct                   Post-diagnosis               4                                               I\$4- I\$36 (I\$10)
  Travel                            Costs for travel association with pre-diagnosis, consultation, diagnosis, treatment, pill collection, DOTS and follow-up treatment visits.                                                                                                                                                                                                                                         Direct                   Both                         18                                              I\$0.17- I\$70 (I\$5)
  Time                              Time and indirect costs associated with time spent seeking/receiving care and lost work time                                                                                                                                                                                                                                                                                       Indirect                 Both                         21                                              I\$0.23- I\$412 (I\$16)^b^
  Caregiver                         Costs to those accompanying patients to TB care visits, retrieving medications on their behalf, or cost of care-giving activities. Direct costs encompass travel expenses, food, or other costs such as paying for an overnight stay when making a long journey. Indirect costs include loss of income and time spent accompanying patients or providing care-giving activities.   Both                     Both                         8                                               I\$0.41- I\$1,510 (I\$11)^c^

^a^ Note: Some medication estimates also include the cost of user/consultation fees; ^b^ Costs include only reported costs of income lost due to time; ^c^ Based on different categories of costs.

Health insurance, prepayment fees, consultation and private provider fees
-------------------------------------------------------------------------

Two studies reported health insurance fees that ranged from I\$2 to I\$3 in Zambia \[[@B41],[@B59]\], and four studies reported consultation or prepayment fees that ranged from I\$2 in Ethiopia \[[@B55]\] and Botswana \[[@B30]\] to I\$7 in Zambia \[[@B58]\]. Patients who did not seek care from the public sector paid fees for care in the private sector. Four studies noted such fees for private services, which ranged from I\$24 (median I\$10) in Zambia \[[@B58]\] to I\$141 in Uganda \[[@B47]\] (see Table [3](#T3){ref-type="table"}). Additionally, one study from Uganda reported the practice of "tipping" healthcare providers in the range of I\$5- I\$40 \[[@B46]\].

###### 

Health insurance, consultation/prepayment fees and private provider fees

  **Author(s) (year)**               **Country**   **Cost estimate (I\$)**   **% Annual per-capita income (entire population)**   **% Annual per-capita income (income-poorest 20% of the population)**   **Notes**
  ---------------------------------- ------------- ------------------------- ---------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  **Health insurance costs**                                                                                                                                                                              
  Aspler, et al. \[[@B41]\]          Zambia        2                         0.43                                                 2                                                                       67% of patients reported paying median health insurance user fees (IQR I\$1.79- I\$1.97)
  Needham, et al. \[[@B59]\]         Zambia        3                         0.69                                                 3^a^                                                                    Mean monthly fees for government-sponsored health insurance (range I\$2-I\$3)
  **Consultation/prepayment fees**                                                                                                                                                                        
  Aspler, et al. \[[@B41]\]          Zambia        4                         0.78                                                 4                                                                       Median one time consultation fee (IQR I\$4- I\$7)
  Mesfin, et al. \[[@B55]\]          Ethiopia      2                         0.93                                                 2                                                                       Mean consultation fees per visit (median I\$0)
  Needham, et al. \[[@B58]\]         Zambia        7                         2                                                    10                                                                      Mean one-time consultation fees (median I\$8)
  Steen and Masonde \[[@B30]\]       Botswana      2                         0.06                                                 0.43^b^                                                                 One-time prepayment outpatient fee
  **Private provider fees**                                                                                                                                                                               
  Chard, S. \[[@B47]\]               Uganda        141                       47                                                   154^c^                                                                  Private clinic treatment costs
  Harper, et al. \[[@B53]\]          The Gambia    44                        11                                                   54^d^                                                                   Costs spent on private treatment
  Needham, et al. \[[@B58]\]         Zambia        24                        6                                                    35                                                                      Mean costs to see a private physician (median I\$15)
  Wyss, et al. \[[@B68]\]            Tanzania      38                        12                                                   29^e^                                                                   Unit cost for private services

^a^ Income share based on 1996 estimates instead of 1995; ^b^ Income share based on 1994 estimates instead of 1993; ^c^ Income share based on 1999 estimates instead of 1998; ^d^ Income share based on 1998 estimates instead of 2000; ^e^ Income share based on 2000 estimates instead of 1996.

Hospitalization, medication, and diagnostic tests costs
-------------------------------------------------------

Ten studies reported hospitalization expenses. Costs ranged from I\$4 in Uganda \[[@B61]\] to over I\$530 in Kenya \[[@B60]\]. Some patients were required to pay hospital admission fees. Patients in Freetown, Sierra Leone paid an average of I\$1 at a missionary hospital and I\$47 at a government hospital, which included the cost of food \[[@B52]\]. Five studies reported medication costs that ranged from I\$20 in Uganda \[[@B46]\] to I\$548 in Nigeria \[[@B42]\] (see Table [4](#T4){ref-type="table"}). Moreover, one study from Kenya reported that patients paid I\$46 monthly for syringes and needles for streptomycin treatment (not including streptomycin itself) \[[@B43]\]. Three studies reported diagnostic test costs other than sputum smears which ranged from I\$7 for chest radiographs \[[@B41]\] to I\$10 for examination, laboratory, and X-ray fees in Tanzania \[[@B68]\].

###### 

Hospitalization, medication, and diagnostic test costs

  **Author(s) (year)**            **Country**    **Cost estimate (I\$)**   **% Annual per-capita income (entire population)**   **% Annual per-capita income (income-poorest 20% of the population)**   **Notes**
  ------------------------------- -------------- ------------------------- ---------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  **Hospitalization costs**                                                                                                                                                                             
  Aspler, et al. \[[@B41]\]       Zambia         14                        3                                                    16                                                                      Median costs (IQR I\$4- I\$19)
  Floyd, et al. \[[@B51]\]        South Africa   119                       3                                                    17^a^                                                                   Mean cost of 18-day hospital stay under DOTS (I\$7 per day)
  Floyd, et al. \[[@B51]\]        South Africa   407                       11                                                   59^a^                                                                   Mean cost of 60-day hospital stay under conventional system (I\$7/day)
  Floyd, et al. \[[@B50]\]        Malawi         498                       262                                                  1048                                                                    Mean cost of 58-day hospital stay under hospital-based strategy for smear-positive patients (I\$9/day)
  Floyd, et al. \[[@B50]\]        Malawi         138                       73                                                   289                                                                     Mean cost of 16-day hospital stay under community-based DOTS strategy for smear-positive patients (I\$9/day)
  Floyd, et al. \[[@B50]\]        Malawi         32                        17                                                   66                                                                      Mean cost of 8-day hospital stay under hospital-based and community-based DOTS strategies for smear-negative patients (I\$9/day)
  Gibson and Boillot \[[@B52]\]   Sierra Leone   1                         0.53                                                 2^b^                                                                    Mean hospital admission fees at a missionary hospital
  Gibson and Boillot \[[@B52]\]   Sierra Leone   47                        18                                                   58^b^                                                                   Mean hospital admission fees at a government hospital
  Mesfin, et al. \[[@B55]\]       Ethiopia       4                         2                                                    5                                                                       Mean cost of hospital admissions (median I\$0)
  Nganda, et al. \[[@B60]\]       Kenya          530                       101                                                  336^c^                                                                  Mean cost of 60-day hospital stay under hospital-based system for smear-positive patients (I\$9/ day) (96% CI I\$5- I\$13)
  Nganda, et al. \[[@B60]\]       Kenya          34                        7                                                    22^c^                                                                   Mean cost of 4-day hospital stay under community-based DOTS for smear-positive patients (I\$9/ day) (96% CI I\$5- I\$13)
  Okello, et al. \[[@B61]\]       Uganda         219                       73                                                   240^d^                                                                  Mean cost of 60-day hospital stay under conventional hospital-based care strategy for smear-positive patients (I\$4/ day)
  Okello, et al. \[[@B61]\]       Uganda         70                        24                                                   77^d^                                                                   Mean cost of 19-day hospital stay under community-based care strategy for smear-positive patients (I\$4/ day)
  Saunderson, P. \[[@B31]\]       Uganda         91                        39                                                   126                                                                     Mean cost for a 2-month hospital stay
  Wilkinson, et al. \[[@B67]\]    South Africa   139                       3.62                                                 20^e^                                                                   Mean cost of 17.5-day hospital stay under community-based DOTS strategy (I\$8/ day)
  Wyss et al. \[[@B68]\]          Tanzania       15                        5                                                    12^f^                                                                   Hospitalization costs reported for one month
  **Medication costs**                                                                                                                                                                                  
  Aspler, et al. \[[@B41]\]       Zambia         15                        3                                                    18                                                                      Median costs for additional medications (IQR I\$9- I\$21)
  Awofeso, N. \[[@B42]\]          Nigeria        548^g^                    121                                                  589^h^                                                                  Mid-range, one-time medication costs (range I\$199- I\$897)^g^
  Chard, S. \[[@B46]\]            Uganda         20                        7                                                    22^i^                                                                   Mean costs for medications (range I\$4- I\$37)
  Kemp, et al. \[[@B54]\]         Malawi         50                        27                                                   106^j^                                                                  Mean costs for smear-negative patients for user fees and drug costs outside of government health facilities (median I\$19)
  Kemp, et al. \[[@B54]\]         Malawi         18                        9                                                    37^j^                                                                   Mean costs for smear-positive patients for user fees and drug costs outside of government health facilities (median I\$6)
  Mesfin, et al. \[[@B55]\]       Ethiopia       22                        12                                                   25                                                                      Mean costs for additional medications (median I\$7)
  **Diagnostic test costs**                                                                                                                                                                             
  Aspler, et al. \[[@B41]\]       Zambia         7                         2                                                    8                                                                       Median cost for chest radiographic (IQR I\$4-I\$7)
  Needham, et al. \[[@B58]\]      Zambia         9                         2                                                    13                                                                      Mean cost for diagnostic tests (unspecified) (median I\$13)
  Wyss, et al. \[[@B68]\]         Tanzania       10                        3                                                    7^f^                                                                    Unit cost for examination, laboratory, and X-rays

^a^ Income share based on 1995 estimates instead of 1994; ^b^ Income share assumed to be 6% by authors in absence of World Bank data; ^c^ Income share based on 1997 estimates instead of 1998; ^d^ Income share based on 1999 estimates instead of 1998; ^e^ Income share based on 1995 estimates instead of 1996; ^f^ Income share based on 2000 estimates instead of 1996; ^g^ Note: the study listed these costs as "prepayment fees," but the costs were actually for medications. Moreover, these medication costs are reported with imprecision (i.e., a wide range), weakening the strength of the conclusion that TB medication costs were high in Nigeria; ^h^ Income share based on 1992 estimates instead of 1993; ^i^ Income share based on 1999 estimates instead of 1998; ^j^ Income share based on 1998 estimates instead of 2000.

Traditional healer and food costs
---------------------------------

Five studies reported that patients paid between I\$3 in Malawi \[[@B44]\] to I\$563 in Uganda \[[@B47]\] to see traditional healers, and four studies reported the cost of food, which ranged from I\$4 (interquartile range (IQR) I\$1- I\$7) in Zambia to I\$36 in Ethiopia and Zambia (median I\$19) for "special food" \[[@B41],[@B48],[@B58]\] (see Table [5](#T5){ref-type="table"}).

###### 

Traditional healer and food costs

  **Author(s) (year)**              **Country**   **Cost estimate (I\$)**   **% Annual per-capita income (entire population)**   **% Annual per-capita income (income-poorest 20% of the population)**   **Notes**
  --------------------------------- ------------- ------------------------- ---------------------------------------------------- ----------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  **Traditional healer costs**                                                                                                                                                                           
  Brouwer, et al. \[[@B44]\]        Malawi        4                         2                                                    9^a^                                                                    Weighted mean of traditional healer costs (range I\$0- I\$28)^b^
  Chard, S. \[[@B47]\]              Uganda        563                       188                                                  618^c^                                                                  One study participant reported this cost for a traditional healer
  Chard, S. \[[@B46]\]              Uganda        15                        5                                                    16^c^                                                                   Mid-point estimate (range I\$2-I\$10). A few patients in the sample reported to pay roughly I\$495
  Needham, et al. \[[@B58]\]        Zambia        17                        4                                                    25                                                                      Average cost to see a traditional healer (median I\$7)
  Wyss, et al. \[[@B68]\]           Tanzania      13                        4                                                    10^d^                                                                   Unit cost to see a traditional healer
  **Food costs**                                                                                                                                                                                         
  Aspler, et al. \[\[[@B41]\]       Zambia        4                         0.78                                                 4                                                                       Median food costs (IQR I\$1- I\$7)
  Datiko and Lindtjørn \[[@B48]\]   Ethiopia      14                        7                                                    15^e^                                                                   Mean food costs for a community-based DOTS treatment program (sd I\$12)
  Datiko and Lindtjørn \[[@B48]\]   Ethiopia      36                        17                                                   37^e^                                                                   Mean food costs for a health-facility-based DOTS treatment program (sd I\$21)
  Kemp, et al. \[[@B54]\]           Malawi        7                         4                                                    15^f^                                                                   Mean food costs for smear-negative patients (median I\$2)
  Kemp, et al. \[[@B54]\]           Malawi        10                        5                                                    21^f^                                                                   Mean food costs for smear-positive patients (median I\$0)
  Needham, et al. \[[@B58]\]        Zambia        3                         1                                                    5                                                                       Mean food cost (median I\$2)
  Needham, et al. \[[@B58]\]        Zambia        36                        9                                                    53                                                                      Mean cost for "special" foods^g^ (median I\$19)

^a^ Income share based on 1998 estimates instead of 1995; ^b^43% of patients in the sample who sought care from traditional healers paid no charge, 21% paid under I\$0.92, 24% paid between I\$0.92 and I\$5, 6% paid between I\$6 and I\$14, and the remaining 6% paid between I\$14 and I\$28; ^c^ Income share based on 1999 estimates instead of 1998; ^d^ Income share based on 2000 estimates instead of 1996; ^e^ Income share based on 2005 estimates instead of 2006; ^f^ Income share based on 1998 estimates instead of 2000; ^g^ Defined as food separate from normal diets such as potatoes, eggs, meat, fruit, and soft drinks \[[@B58]\].

Travel costs
------------

Eighteen studies reported travel costs for patients, families, or guardians for single visits or for multiple visits during treatment. Costs ranged from less than I\$1 in South Africa for a single health clinic visit \[[@B51],[@B63]\] to I\$70 in Ethiopia for pretreatment transportation costs \[[@B65]\] (see Table [6](#T6){ref-type="table"}). Travel time also varied from 48 minutes in Cape Town, South Africa \[[@B63]\] and Kampala, Uganda \[[@B46]\] to almost 70 hours in Ethiopia under a health-facility based DOTS system for a single visit \[[@B48]\]. One study from Zambia distinguished between pre and post diagnosis travel costs: pre-diagnosis travel costs were I\$3 (IQR I\$1- I\$7) while post-diagnosis costs were I\$11 (IQR I\$4- I\$29) \[[@B41]\]. In addition to travel costs, one study reported accommodation costs (in Ethiopia) \[[@B55]\].

###### 

Travel costs

  **Author(s) year**                **Country**    **Cost estimate (I\$)**   **% monthly per-capita income (entire population)**   **% monthly per-capital income (income-poorest 20% of the population)**   **Notes**
  --------------------------------- -------------- ------------------------- ----------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Aspler, et al. \[[@B41]\]         Zambia         3                         8                                                     43                                                                        Median costs for pre-diagnosis (IQR I\$1- I\$7)
  Aspler, et al. \[[@B41]\]         Zambia         12                        31                                                    171                                                                       Median costs for pill collection visits (IQR I\$4- I\$29)
  Aspler, et al. \[[@B41]\]         Zambia         4                         10                                                    57                                                                        Median costs for follow-up visits (IQR I\$2- I\$4)
  Bevan, E. \[[@B43]\]              Kenya          5                         11                                                    35                                                                        Daily cost to travel to a designated DOTS center
  Cambanis, et al. \[[@B45]\]       Ethiopia       7                         47                                                    100^a^                                                                    Mean costs for transport to a health facility
  Chard, S. \[[@B46]\]              Uganda         3                         14                                                    45^b^                                                                     Mean transportation costs to a health facility in Kampala
  Chard, S. \[[@B46]\]              Uganda         5                         21                                                    67^b^                                                                     Mean transportation costs to a health facility in Mukono
  Datiko and Lindtjorn \[[@B48]\]   Ethiopia       2                         14                                                    31^c^                                                                     Mean transport costs for a community-based DOTS treatment program (sd I\$5)
  Datiko and Lindtjorn \[[@B48]\]   Ethiopia       15                        88                                                    188^c^                                                                    Mean transport costs for a health facility-based DOTS treatment program (sd I\$43)
  Edginton, et al. \[[@B49]\]       South Africa   3                         0.96                                                  7^d^                                                                      Mid-point costs for 69% of hospital attendees and 48% of clinic attendees (range I\$0.52-I\$5)^e^
  Floyd, et al. \[[@B51]\]          South Africa   12                        4                                                     20^f^                                                                     Mean travel cost for a hospital visit
  Floyd, et al. \[[@B51]\]          South Africa   2                         0.74                                                  4^f^                                                                      Mean travel cost for a health clinic visit
  Floyd, et al. \[[@B51]\]          South Africa   0.17                      0.05                                                  0.30^f^                                                                   Mean travel cost for a health clinic DOTS visit
  Floyd, et al. \[[@B51]\]          South Africa   0.85                      0.27                                                  1^f^                                                                      Mean travel cost for a TB ward DOTS visit
  Floyd, et al. \[[@B50]\]          Malawi         4                         26                                                    102                                                                       Mean costs for visit to a health center to collect drugs for smear-positive and -negative patients under hospital and community-based strategies (I\$18 for average 5 visits)
  Harper, et al. \[[@B53]\]         The Gambia     0.55                      2                                                     8^g^                                                                      Mean daily fare to attend a TB clinic (range I\$0.44-I\$0.66)
  Kemp, et al. \[[@B54]\]           Malawi         18                        116                                                   456^h^                                                                    Mean transport costs for smear-positive patients (median I\$11)
  Kemp, et al. \[[@B54]\]           Malawi         13                        81                                                    319^h^                                                                    Mean transport costs for smear-negative patients (median I\$5)
  Mesfin, et al. \[[@B55]\]         Ethiopia       11                        72                                                    155                                                                       Mean transport costs for visiting a public health facility pre-diagnosis
  Needham, et al. \[[@B58]\]        Zambia         9                         26                                                    150                                                                       Mean transportation cost during treatment (median I\$3)
  Nganda, et al. \[[@B60]\]         Kenya          9                         20                                                    67^i^                                                                     Mean cost for a visit to collect drugs from a health facility for smear-positive patients under conventional and community-based strategies for smear-positive patients (I\$44 for average 5 visits)^j^
  Okello, et al. \[[@B61]\]         Uganda         6                         24                                                    78^k^                                                                     Mean costs to the nearest health facility in an outpatient system and costs to collect drugs under the conventional hospital-based care strategy and the community-based care strategy for smear-positive patients (I\$37 for average 5 visits)
  Sinanovic, et al. \[[@B63]\]      South Africa   0.40                      0.13                                                  0.69^m^                                                                   Mean cost for monitoring and collection of drugs and a clinic-based DOTS visit in Guguletu, Cape Town (95% CI I\$0.20- I\$0.60)
  Sinanovic, et al. \[[@B63]\]      South Africa   0.30                      0.09                                                  0.52^m^                                                                   Mean cost for monitoring and collection of drugs and a clinic-based DOTS visit in Nyanga, Cape Town (95% CI I\$0.10- I\$0.50)
  Vassall, et al. \[[@B65]\]        Ethiopia       70                        444                                                   952                                                                       Mean pretreatment transportation costs (median I\$4)^n^
  Wilkinson, et al. \[[@B67]\]      South Africa   5                         2                                                     9 ^o^                                                                     Average cost of a visit to a village clinic^p^
  Wilkinson, et al. \[[@B67]\]      South Africa   20                        6                                                     34 ^o^                                                                    Average cost of a visit to a hospital^p^
  Wilkinson, et al. \[[@B67]\]      South Africa   1                         0.43                                                  2 ^o^                                                                     Average cost of a village clinic DOTS visit, a community health worker DOTS visit, and a non-health worker DOTS visit^p^
  Wyss, et al. \[[@B68]\]           Tanzania       9                         32                                                    83 ^q^                                                                    Weekly transportation costs

^a^ Income share based on 2005 estimates instead of 2004; ^b^ Income share based on 1999 estimates instead of 1998; ^c^ Income share based on 2005 estimates instead of 2006; ^d^ Income share based on 1993 estimates instead of 1994; ^e^ 29% of hospital attendees and 52% of clinic attendees reported to pay no cost in transportation fees, and 2% of hospital attendees and 0 clinic attendees paid more than I\$5; ^f^ Income share based on 1995 estimates instead of 1996; ^g^ Income share based on 1998 estimates instead of 2000; ^h^ Income share based on 1998 estimates instead of 2000; ^i^ Income share based on 1997 estimates instead of 1998; ^j^ The conventional was approach used until 1997 in which new patients were hospitalized for the first month of treatment and subsequently provided unsupervised treatment for the next 11 months. The community-based approach was used after 1997 in which patients spent the first 2 months of treatment in DOTS outpatient programs and the remaining 6 months of treatment in unsupervised outpatient visits; ^k^ Income share based on 1999 estimates instead of 1998; ^l^ Income share based on 2004 estimates instead of 2005; ^m^ Income share based on 1995 estimates instead of 1997; ^n^ Note: these costs are over several months---the authors did not report single transportation costs; ^o^ Income share based on 1995 estimates instead of 1996; ^p^ Note: these costs include indirect time costs; ^q^ Income share based on 2000 estimates instead of 1996.

Time costs
----------

Twenty-one studies reported time costs. Clinic visit wait time varied from 30 minutes in Limpopo Province, South Africa \[[@B49]\] to 111 minutes in Kampala, Uganda \[[@B46]\]. One study from Uganda reported that patients spent on average 22 minutes for a volunteer-supervised outpatient DOTS visit or I\$0.23 (95% CI I\$0.00- I\$0.42) in lost income, and an average of 110 minutes for a health-facility visit, or I\$1 (95% CI I\$1- I\$2) in lost income \[[@B61]\].

Lost work time varied by treatment system. For hospitalized patients in South Africa, each hospital day led to an average of 402 minutes of lost work time (I\$7 in lost income) compared to 128 minutes (I\$2) for a health clinic visit, 50 minutes (I\$0.85) for a DOTS visit with a community health worker chosen as a treatment supervisor, and 4 minutes (I\$0.51) with another type of health worker chosen as a supervisor \[[@B51]\]. In Malawi patients lost an average of 22 workdays resulting in an average income loss of I\$68 \[[@B54]\]. Two studies in Zambia found that patients missed an average of 18 workdays before being diagnosed with TB \[[@B58]\] and 48 days of missed work in total \[[@B59]\]. Foregone earnings reported for any type of care-seeking activity ranged from I\$3 in South Africa \[[@B63]\] to I\$169 in Tanzania \[[@B68]\].

Reported impact on income
-------------------------

Five studies surveyed patients on their salaries and reported the impact of TB patient costs on household incomes \[[@B41],[@B55],[@B58],[@B59],[@B65]\]; one study used average household income estimates from an external source to calculate the impact of TB patient costs on household incomes \[[@B54]\]. In Malawi, patients spent between 129% and 244% of their mean monthly income (MMI) on TB diagnosis \[[@B54]\]. In Zambia, patients spent 16% of their MMI on transportation costs and 66% of their MMI on food \[[@B59]\]. Direct medical expenditures ranged from between 10% of MMI for men and 132% of MMI for women in Zambia \[[@B41]\] to 31% for all patients in Ethiopia \[[@B55]\], while non-medical expenditures ranged from 42% in Ethiopia \[[@B55]\] to 55% of MMI in Zambia \[[@B58]\]. In Ethiopia, 48% and 35% of annual household income was lost due to TB treatment and pretreatment costs, respectively \[[@B65]\].

Reported direct, indirect and total costs
-----------------------------------------

Eight studies reported aggregated overall direct costs, and six studies reported aggregated overall indirect costs incurred by patients (although authors defined direct and indirect costs differently). Reported direct costs ranged from I\$11 in Zambia \[[@B41]\] to over I\$527 in Ethiopia \[[@B65]\], while indirect costs ranged from I\$21 in Zambia \[[@B41]\] to I\$145 in Ethiopia \[[@B55]\]. Thirteen studies reported overall total costs (direct and indirect), which ranged from I\$2 in South Africa \[[@B63]\] to I\$584 in Uganda \[[@B31]\] (see Table [7](#T7){ref-type="table"}).

###### 

Reported direct, indirect and total costs

  **Author(s) year**                      **Country**    **Cost estimate (I\$)**   **% Annual per-capita income (entire population)**   **% Annual per-capita income (income-poorest 20% of the population)**   **Notes**
  --------------------------------------- -------------- ------------------------- ---------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Direct costs**                                                                                                                                                                                              
  Aspler, et al. \[[@B41]\]               Zambia         11                        2                                                    13                                                                      Total direct costs including medical and non-medical costs (IQR I\$6- I\$17)
  Datiko and Lindtjorn \[[@B48]\]         Ethiopia       17                        8                                                    17                                                                      Direct patient costs under community-based DOTS (sd I\$12)
  Datiko and Lindtjorn \[[@B48]\]         Ethiopia       49                        24                                                   51                                                                      Direct patient costs under health facility-based DOTS (sd I\$44)
  Kemp, et al. \[[@B54]\]                 Malawi         39                        21                                                   83^a^                                                                   Mean total direct costs for smear-positive patients (median I\$19)
  Kemp, et al. \[[@B54]\]                 Malawi         74                        40                                                   156^a^                                                                  Mean total direct costs for smear-negative patients (median I\$38)
  Mesfin, et al. \[[@B55]\]               Ethiopia       114                       60                                                   129                                                                     Mean total direct costs (median I\$61; IQR I\$26- I\$132)
  Needham, et al. \[[@B57]\]              Zambia         64                        16                                                   73                                                                      Total mean direct costs
  Needham, et al. \[[@B58]\]              Zambia         14                        3                                                    20                                                                      Total mean direct medical costs (median I\$5)
  Needham, et al. \[[@B58]\]              Zambia         31                        8                                                    45                                                                      Total mean direct non-medical costs (median I\$14)
  Vassall, et al. \[[@B65]\]              Ethiopia       527                       277                                                  595                                                                     Total mean direct pretreatment costs including transport and non-transport costs for (median I\$66)
  Wandwalo, et al. \[[@B66]\]             Tanzania       59                        17                                                   33^b^                                                                   Total direct costs under a health facility-based DOTS strategy
  Wandwalo, et al. \[[@B66]\]             Tanzania       13                        4                                                    8^b^                                                                    Total direct costs under a community-based DOTS strategy
  **Indirect Costs**                                                                                                                                                                                            
  Aspler, et al. \[[@B41]\]               Zambia         21                        5                                                    25                                                                      Median total indirect costs (IQR I\$11- I\$39)
  Datiko and Lindtjorn \[[@B48]\]         Ethiopia       18                        9                                                    18                                                                      Mean indirect cost under community-based DOTS
  Datiko and Lindtjorn \[[@B48]\]         Ethiopia       48                        50                                                   24                                                                      Mean indirect cost under health facility-based DOTS
  Mesfin, et al. \[[@B55]\]               Ethiopia       145                       76                                                   164                                                                     Average indirect costs from first consultation to diagnosis including income lost and travel time cost (median I\$44; IQR I\$15- I\$101)
  Mesfin, et al. \[[@B55]\]               Ethiopia       54                        28                                                   60                                                                      Average indirect costs prior to diagnosis (median I\$26.) including income last and travel time cost
  Needham, et al. \[[@B58]\]              Zambia         99                        25                                                   145                                                                     Total lost income (median I\$37)
  Vassall, et al. \[[@B65]\]              Ethiopia       44                        23                                                   50                                                                      Total mean indirect pretreatment costs (median I\$0)
  Wandwalo, et al. \[[@B66]\]             Tanzania       56                        16                                                   32^b^                                                                   Total indirect costs under a health facility-based DOTS strategy
  Wandwalo, et al. \[[@B66]\]             Tanzania       19                        5                                                    11^b^                                                                   Total indirect costs under a community-based DOTS strategy
  **Total Costs**                                                                                                                                                                                               
  Aspler, et al. \[[@B41]\]               Zambia         34                        7                                                    41                                                                      Total median costs per patients (IQR I\$19-I\$56) in which direct and indirect costs comprised 34% and 62%, respecitvely
  Chard, S. \[[@B46]\]                    Uganda         25                        8                                                    27^c^                                                                   Total reported costs for biomedical treatment
  Datiko and Lindtjorn \[[@B48]\]         Ethiopia       34                        17                                                   36^d^                                                                   Total patient costs under community-based DOTS (sd I\$16)
  Datiko and Lindtjorn \[[@B48]\]         Ethiopia       99                        48                                                   104^d^                                                                  Total patient costs under health facility-based DOTS (sd I\$50)
  Floyd, et al. \[[@B51]\]                South Africa   155                       4                                                    23^e^                                                                   Total cost to patients under DOTS
  Floyd, et al. \[[@B51]\]                South Africa   461                       12                                                   67^e^                                                                   Total cost to patients under the conventional system^f^
  Gibson and Boillot \[[@B52]\]           Sierra Leone   26                        10                                                   33^g^                                                                   Total cost for patients under the National Leprosy and TB Control Program
  Mesfin, et al. \[[@B55]\]               Ethiopia       259                       136                                                  292                                                                     Mean total costs (median I\$119; IQR I\$53- I\$242)
  Needham, et al. \[[@B58]\]              Zambia         68                        17                                                   100                                                                     Total patient costs (median I\$32)
  Saunderson, P.R. \[[@B31]\]             Uganda         584                       249                                                  809                                                                     Total cost under the strategy that utilizes hospitalization for the first two months of treatment followed by an outpatient continuation phase for 4--10 months.
  Sinanovic and Kumaranayake \[[@B64]\]   South Africa   102                       3                                                    17^h^                                                                   Total cost per patient attending a public-non-governmental organization partnership site (95% CI I\$73- I\$123)
  Sinanovic and Kumaranayake \[[@B64]\]   South Africa   95                        2                                                    16^h^                                                                   Total cost per patient attending a public-non-governmental organization partnership site (95% CI I\$82- 104)
  Sinanovic and Kumaranayake \[[@B64]\]   South Africa   264                       7                                                    44^h^                                                                   Total cost per patient attending a public hospital (95% CI I\$251- I\$274)
  Sinanovic and Kumaranayake \[[@B64]\]   South Africa   317                       8                                                    53^h^                                                                   Total cost per patient attending a public hospital (95% CI I\$293- I\$363)
  Sinanovic, et al. \[[@B63]\]            South Africa   2                         0.044                                                0.24^i^                                                                 Total cost for a clinic DOTS visit, where clinic used for DOTS and total cost for monitoring/collection of drugs in Nyanga (95% CI I\$1- I\$2)
  Sinanovic, et al. \[[@B63]\]            South Africa   2                         0.041                                                0.23^i^                                                                 Total cost for a clinic DOTS visit, where clinic used for DOTS and total cost for monitoring/collection of drugs in Guguletu (95% CI I\$1- I\$2)
  Sinanovic, et al. \[[@B63]\]            South Africa   1                         0.01                                                 0.08^i^                                                                 Total cost for a DOTS visit, where community treatment supporter u used for in Guguletu (95% CI I\$1- I\$2)
  Vassall, et al. \[[@B65]\]              Ethiopia       567                       298                                                  639                                                                     Total mean pretreatment costs
  Wandwalo, et al. \[[@B66]\]             Tanzania       116                       32                                                   65^b^                                                                   Total costs under a health facility-based DOTS strategy
  Wandwalo, et al. \[[@B66]\]             Tanzania       32                        9                                                    18^b^                                                                   Total costs under a community-based DOTS strategy
  Wilkinson, et al. \[[@B67]\]            South Africa   183                       5                                                    27^j^                                                                   Total costs for patients treated under community-based DOTS strategy.

^a^ Income share based on 1998 estimates instead of 2000; ^b^ Income share based on 2000 estimates instead of 2005; ^c^ Income share based on 1999 estimates instead of 1998; ^d^ Income share based on 2005 estimates instead of 2006; ^e^ Income share based on 1995 estimates instead of 1996; ^f^ The conventional system hospitalizes patients for the first two months of treatment; ^g^ Income share assumed to be 6% by authors in absence of World Bank data; ^h^ Income share based on 2000 estimates instead of 2001; ^i^ Income share based on 1995 estimates instead of 1997; ^j^ Income share based on 1995 estimates instead of 1996; ^k^ Income share based on 2000 estimates instead of 1996.

Five studies reported the percentage of all costs that patients paid out-of-pocket. In South Africa, out-of-pocket expenses varied by district in which patients were responsible for paying between 13% and 34% of all costs \[[@B51]\]. Similarly, in Tanzania patients paid between 13% and 30% of total costs in community-based DOTS and health facility-based DOTS programs, respectively \[[@B66]\]. In Malawi and Ethiopia, patients paid close to 50% of total costs of their care.

Caregiver and guardian costs
----------------------------

Eight studies reported both direct and indirect costs incurred by TB patients' guardians or caregivers. Direct costs included transportation costs that ranged from less than I\$1 (standard deviation \[SD\] I\$4) under a community-based DOTS program in Ethiopia \[[@B48]\] to I\$27 in Botswana \[[@B56]\]. The amount of time spent traveling for one care-related visit ranged from 20 minutes in Botswana \[[@B56]\] to 17 hours (median 0) in Ethiopia \[[@B55]\]. Other direct costs for caregivers included food costs that ranged from I\$3 (standard deviation \[SD\] I\$5) in Ethiopia \[[@B48]\] to I\$1,209 in Botswana \[[@B56]\] and time spent providing care-giving activities, which ranged from 1 hour each day in Botswana \[[@B59]\] to 6 days (median 1) for hospitalized patients in Ethiopia \[[@B55]\]. Indirect costs included foregone earnings for caregivers which ranged from I\$19 (median \$10) in Zambia \[[@B58]\] to I\$89 in Ethiopia \[[@B55]\]. Total reported caregiver cost ranged from I\$24 (median I\$12) in Zambia \[[@B58]\] to I\$1510 under a home-based care strategy in Botswana \[[@B56]\].

Catastrophic costs
------------------

Twenty studies reported costs that were found to be catastrophic for those with average income, and twenty-five studies had costs that were catastrophic for the lowest income earners (see Table [8](#T8){ref-type="table"}). Catastrophic costs constituted between 11% of average annual income in The Gambia for private providers \[[@B53]\] and almost three times average annual income in Ethiopia for total pretreatment costs \[[@B65]\]. For those in the income-poorest 20% of a country's population, catastrophic costs constituted between 10% of annual income for traditional healers in Tanzania \[[@B68]\] to roughly ten times annual income for hospitalization costs in Malawi \[[@B50]\].

###### 

Types of catastrophic costs

  **Author(s) (year)**                            **Country**    **Catastrophic Costs for Average Income Earners**                             **Range (% of annual income)**   **Catastrophic Costs for Lowest 20%**                                                                                                                        **Range (% of annual income)**
  ----------------------------------------------- -------------- ----------------------------------------------------------------------------- -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------
  Aspler, et al. (1998) \[[@B41]\]                Zambia         Total                                                                         12                               Total, direct, indirect, pre-diagnosis, treatment, time, transportation, medication, hospitalization, direct clinic-based DOTS, indirect clinic-based DOTS   12-40
  Awofeso, N. (1998) \[[@B42]\]                   Nigeria        Medication                                                                    121                              Medication                                                                                                                                                   589
  Bevan, E. (1997) \[[@B43]\]                     Kenya          \_\_\_                                                                        \_\_\_                           Medication, syringes and needles                                                                                                                             11-32
  Chard, S. (2001) \[[@B46]\]                     Uganda         Medication, traditional healer, "tipping" providers                           12-165                           Medication, traditional healer, "tipping" providers                                                                                                          41-544
  Chard, S. (2009) \[[@B47]\]                     Uganda         Private provider, traditional healer                                          47-188                           Private provider, traditional healer                                                                                                                         154-618
  Datiko and Lindtjørn (2010) \[[@B48]\]          Ethiopia       Total, travel, time, caregiver, direct, food                                  17-48                            Total, travel, time, caregiver, direct, food                                                                                                                 15-104
  Floyd, et al. (2003) \[[@B50]\]                 Malawi         Travel, hospitalization, DOTS visit                                           13-262                           Travel, hospitalization                                                                                                                                      18-1043
  Floyd, et al. (1997) \[[@B51]\]                 South Africa   Total, hospitalization                                                        11-12                            Total, hospitalization                                                                                                                                       17-67
  Gibson, et al. (1998) \[[@B52]\]                Sierra Leone   pre-program, program, hospital admission fees                                 17-88                            Total, pre-program, program, hospital admission fees                                                                                                         32-287
  Harper, et al. (2003) \[[@B53]\]                The Gambia     Private treatment                                                             11                               Private treatment                                                                                                                                            54
  Kemp, et al. (2007) \[[@B54]\]                  Malawi         Direct, income lost, user fees and medication, pre-diagnosis                  21-40                            Direct, income lost, user fees and medication, pre-diagnosis, food, travel                                                                                   15-155
  Mesfin, et al. (2010) \[[@B55]\]                Ethiopia       Medical, non-medical, indirect, direct, medication, caregiver, total          11-136                           Medical, non-medical, indirect, direct, medication, caregiver, travel, total                                                                                 12-292
  Moalosi, et al. (2003) \[[@B56]\]               Botswana       Total caregiver costs Caregiver hospitalization Caregiver food and supplies   13-51                            Total caregiver costs, caregiver hospitalization, caregiver medication, caregiver food and supplies                                                          29-258
  Needham, et al. (1996) \[[@B57]\]               Zambia         Total medical, direct, income lost                                            16-148                           Total medical, total non-medical, direct, income lost                                                                                                        43-688
  Needham, et al. (1998) \[[@B58]\]               Zambia         Total, indirect, pre-diagnosis, non-medical, food                             11-47                            Total, indirect, pre-diagnosis, non-medical, medical, food, diagnostic tests, caregiver, private provider, traditional healer, consultation fees, travel,    15-214
  Needham, et al. (2004) \[[@B59]\]               Zambia         \_\_\_                                                                        \_\_\_                           Transportation                                                                                                                                               11
  Nganda, et al. (2003) \[[@B60]\]                Kenya          Hospitalization, travel                                                       33-101                           Hospitalization, travel                                                                                                                                      22-336
  Okello, et al. (2003) \[[@B61]\]                Uganda         Hospitalization, travel                                                       12-73                            Hospitalization, travel                                                                                                                                      40-241
  Saunderson, P.R. (1995) \[[@B31]\]              Uganda         Total, hospitalization, pre-diagnosis, indirect                               34-249                           Total, hospitalization, pre-diagnosis, indirect                                                                                                              111-809
  Sinanovic, et al. (2003) \[[@B63]\]             South Africa   \_\_\_                                                                        \_\_\_                           Total                                                                                                                                                        11-43
  Sinanovic and Kumaranay-ake (2006) \[[@B64]\]   South Africa   \_\_\_                                                                        \_\_\_                           Total, time, travel                                                                                                                                          11-53
  Vassall, et al. (2010) \[[@B65]\]               Ethiopia       Direct, indirect, travel and total pretreatment                               23-298                           Direct, indirect, travel and total pretreatment                                                                                                              50-639
  Wandwalo, et al. (2005) \[[@B66]\]              Tanzania       Total, direct, indirect                                                       16-32                            Total, direct, indirect                                                                                                                                      18-65
  Wilkinson, et al. (1997) \[[@B67]\]             South Africa   \_\_\_                                                                        \_\_\_                           Total, hospitalization                                                                                                                                       20-27
  Wyss, et al. (2001) \[[@B68]\]                  Tanzania       Private provider                                                              12                               Traditional healer, private provider, hospitalization                                                                                                        10-29

Two aspects of our extracted data are important to note in this context: First, we extracted data for a range of different cost categories (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}). For all cost categories, there are at least a few studies reporting catastrophic costs according to our definition both for those with average income and those with the average income among the income-poorest 20% of the population: traditional healer, food, travel, private provider, medication, "tipping" providers, hospitalization, caregiver, and overall direct, indirect and total costs. Second, the extracted costs are presented in the tables in the units they were reported in the original papers because we did not have sufficient information, either from the papers or external sources, to allow translation into a common unit. However, catastrophic costs were found in all units of reported costs, including per-visit, per time period, and per treatment course and in both the pre- and post-diagnosis periods.

Discussion
==========

In expanding on a previous review of TB patient costs in sub-Saharan Africa \[[@B23]\], we extended the evidence base on TB patient costs in sub-Saharan Africa through screening of additional databases and broadening the study design inclusion criteria. We have further added to the literature by systematically identifying the particular types of costs TB patient incur and by systematically reviewing the evidence on the cost quantities for each cost type. Our review furthermore provides benchmarks for the magnitude of these cost burdens by comparing them to average income earners and the average income of the income-poorest 20% of the population.

The data reviewed here demonstrate that direct and indirect patient costs for TB patients and their households can be substantial and often "catastrophic" for average income earners and, in particular, for those in the income-poorest 20% of the population---the proportion of the population most at-risk of acquiring TB. The data we extracted from the literature thus suggest that expenditures for TB treatment and care can cause or exacerbate poverty. TB patients in sub-Saharan Africa incur both substantial direct and indirect costs before, during, and after a TB diagnosis. The largest costs these patients incur are for hospitalization, medication, transportation, and treatment or care in the private sector. In addition, caregivers incur substantial indirect, or time costs, of providing care or support for TB patients.

Results also show that total TB treatment and care costs vary greatly between studies: from only I\$2 in South Africa \[[@B63]\] to almost \$600 in Uganda \[[@B31]\] in total estimated costs. Additionally, the types of costs that patients often pay are numerous: eleven main categories of costs were captured in this review, and nine of the thirty studies reported costs in at least five of these cost categories. Though patients in sub-Saharan Africa often do not incur all of these fees, merely paying for one or some of them can have substantial impacts on their economic circumstances.

Patient costs may negatively impact health-seeking behaviors, leading to delays in hospital presentation, further worsening of disease and increasing risk of disease spread \[[@B16]\]. Patients adopt several mechanisms to cope with these costs ranging from asset selling, borrowing, and diversifying income-generating activities \[[@B19],[@B20]\]. In order to alleviate the financial burden borne by TB patients, policy makers should consider incorporating policies to support patients receiving TB treatment into general financing and risk-pooling strategies, such as tax-based or social insurance systems as used by many developed and, increasingly, developing economies. While in some settings strategies aimed at reducing patient costs incurred when utilizing healthcare may be feared to lead to increases in demand for healthcare exceeding the underlying need, in many developing countries like those in sub-Saharan Africa, healthcare demand is currently far below need, including for the priority diseases TB and HIV, so that financial and non-financial support for healthcare seeking is likely to contribute substantially to improving population health \[[@B70],[@B71]\]. In addition to the direct benefits to the treated patient, TB treatment also reduces onward transmission of the disease in the community. This positive externality needs to be taken into account when considering public investments to decrease the costs patients bare when utilizing TB care.

Comparable types and extents of costs incurred by patients in sub-Saharan have been found in studies assessing the household financial burden of other infectious diseases including malaria and HIV/AIDS. Although some health districts in sub-Saharan Africa provide free care for HIV/AIDS and malaria patients, studies assessing the burden of expenditures for malaria and HIV/AIDS-affected households have found that costs are commonly "catastrophic," a general finding that conforms with our results for the case of TB. Moreover, the main types of costs that patients and households incurred based on these studies were similar to those found in our review: direct costs of transportation for patients and caregivers, medications, diagnostic tests, hospitalization, food, medical consultations, and traditional healers, as well as the indirect costs such as loss of time at work or school \[[@B34],[@B72]-[@B76]\].

More research needs to be done in order to assess the burden of costs to TB patients in other geographical areas, including in the 36 other countries in sub-Saharan Africa for which our systematic review could not identify any empirical estimates of TB treatment and care costs. While our results broadly support calls for health policy changes to alleviate patients' financial burdens of TB treatment, it is unclear which particular interventions will be most effective and cost-effective. Examples of interventions that can reduce the direct patient expenditures for TB treatment include free transport between communities and TB treatment facilities, food vouchers given to TB patients when visiting a facility, and systematic elimination of user fees. Interventions that can reduce indirect patient expenditures for TB treatment include improved health infrastructure, such as, additional TB treatment facilities, better transport infrastructure (to decrease the time spent travelling from a household to a healthcare facility), as well as improved patient scheduling systems (to decrease patient wait times at healthcare facilities).

Finally, since we find that patients in some countries spend substantial amounts of money for TB treatment and care in the private sector despite public-sector TB programs that offer some services free of charge, interventions to decrease the demand for private-sector TB treatment and care could reduce the financial burden to TB patients. Such interventions could improve media campaigns to ensure that patients are aware of where and when they can access public-sector TB treatment and health sector reforms leading to increased quality of care in the public sector. Rigorous evaluation studies, accompanying the implementation of such interventions, will contribute to our understanding of their performance and impact on patient healthcare expenditures and population health outcomes.

Limitations
-----------

There are several limitations of this review: First, we included studies that were conducted from 1994 to present. Earlier studies might not be generalizable to current strategies because TB control program policies may have changed since their publication. Second, although no official criteria exist for assessing studies on patient costs, other systematic reviews of patient costs have used various quality assessment criteria for evaluating study quality \[[@B23],[@B77]-[@B79]\]. Due to our broader study inclusion criteria, we were unable to adopt similar formal criteria for evaluating study quality beyond ensuring that studies had clearly defined objectives, clearly defined study populations, and a quantitative measure of patient-costs. This limitation may have led to a relatively higher weight placed on results from "low quality" studies in the interpretation and discussion of the summary findings from our systematic review than would have been the case if we could have more clearly distinguished between "low" and "high quality" studies.

Third, many studies assessed only a few specific types of costs, so comparing total cost burden to patients across studies is difficult and may be underestimated. Similarly, the studies that reported aggregate direct and indirect costs might have defined direct and indirect costs differently, so these reported measures might not be comparable. Additionally, since costs were measured differently and may reflect different time periods, (for instance some travel costs were measured as one-time costs, and others were measured over the entire course of treatment), comparing these cost burdens on patients' average annual or monthly income are difficult and must be interpreted with caution.

Moreover, only five studies directly surveyed patients on their incomes. In our estimation of the impact of TB patient costs on patients' economic circumstances, we thus had to rely on national income estimates. However, it is very likely that TB patients' average income deviates substantially from the national average, so that our relative measures of the out-of-pocket cost burden to patients and households may be biased.

Furthermore, since data on income shares of the income-poorest 20% of the population were missing for several country-years, we used estimates from the closest years for which data were available for a country, but this could potentially yield inaccurate estimates of per capita GDP for this portion of the population. Finally, evidence on TB patient costs was only available for 11 out of 47 countries in sub-Saharan Africa. Results from these studies cannot be extrapolated to the rest of the continent, and it is possible that patients in other parts of Africa might incur lower TB patient costs.

Conclusion
==========

Tuberculosis can place considerable financial and economic burden on patients and households in sub-Saharan Africa. Here, we identified 30 relevant studies investigating TB patient costs in sub-Saharan Africa before, during and after diagnosis and treatment for TB. We found that patient costs vary considerably both by total amounts and according to the different types of costs incurred by patients in DOTS and non-DOTS settings. In many settings, patient costs were found to be "catastrophic" in that they amounted to 10% or more of average annual incomes. These costs have the potential to financially strain patients and their households, leading to detrimental effects such as delayed care seeking and increased default rates of TB patients, potentially fueling the spread of TB or increasing multi-drug resistant TB in sub-Saharan Africa. Future research needs to assess which interventions and health systems reforms are most effective and cost-effective in reducing the financial burdens that patients incur when seeking TB treatment and care.
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